lc

  • Agilent Technologies introduces commercial hybrid supercritical fluid/UHPLC system

    The 1260 Infinity Hybrid SFC/UHPLC system delivers LC-like sensitivity over the UHPLC power range.

    lc | 03 April 2012

  • Thermo Fisher Scientific introduces Nano-UHPLC system

    Thermo Fisher Scientific announced that the Center for Experimental Bioinformatics (CEBI) at the University of Southern Denmark is using Thermo Scientific nano-ultra high performance liquid chromatography (UHPLC) technology to accelerate productivity and improve efficiencies during its proteomics research. Implementation of the Thermo Scientific EASY-nLC 1000 has enabled 34 percent more peptide and 22 percent more protein identifications within the CEBI laboratory, significantly increasing productivity. Additionally, the instrument has improved separations and facilitated the analysis of more complex samples within the laboratory.

    lc | 25 November 2011

  • Novartis increases growth potential through integration of Alcon

    Alcon is innovative new growth platform with leading position in eye care segment.

    lc | 13 September 2011

  • Agilent Technologies’ LC/MS manufacturing achieves ISO 13485 certification

    Achieves internationally recognized standard of quality management for the design and manufacture of medical devices.

    lc | 08 September 2011

  • AllCells expands operations in Shanghai, China

    AllCells LLC announced that it has completed the relocation and operational expansion of its Shanghai-based facilities. AllCells-Shanghai is now situated in Ju Ke Park near the center of the city with almost 10,000 sq ft of laboratory, production…

    lc | 02 September 2011

  • CSL welcomes pandemic agreement

    CSL Biotherapies welcomes news of a decision by the World Health Assembly to adopt the Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits. The Framework is the culmination of se…

    lc | 20 May 2011

  • Patients with ALK-positive advanced NSCLC respond to crizotinib

    Data published by Pfizer showed that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one…

    lc | 25 February 2011

  • Norvatis owns 77 percent of Alcon

    Novartis has completed its purchase of Alcon stock from Nestle resulting in 77 percent ownership of Alcon. This has been achieved by completing the acquisition of the remaining 52 percent of Alcon shares owned by Nestle for a total of US$ 28.3 billi…

    lc | 26 September 2010

  • HPLC columns for peptide purification

    Biotage has launched a range of HPLC columns optimized for peptide purification. The Resolux line delivers purification solutions for very short peptides up to large chains by offering consumables in three different pore sizes. This line will be…

    lc | 19 September 2010

  • Phase three results of sunitinib with erlotinib in NSCLC

    Pfizer announces that the Sun 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in progression-free but not in overall survival in patients with previously treated advanced no…

    lc | 16 September 2010

Page 1 Next > Last >>